Humabs BioMed, subsidiary of Vir Biotechnology

Great news! Important recommendation for HBD patients!

Great data!

People with #HepatitisDelta deserve innovative treatment options, better care, and more hope. Read more in Dr. Nancy Reau’s latest article in Healio: https://bit.ly/3Z3N2G4 American Association for the Study of Liver Diseases (AASLD)’s #TLM24 starts tomorrow, and with it the opportunity to share progress and exciting data, and engage with patients, peers, and experts to drive change, not only in hepatitis delta but also in #HepatitisB. I’m excited to be in San Diego and look forward to many inspiring discussions!

It is an exhilarating week for Vir Biotechnology, Inc. and for me personally! I am excited to welcome a new team of skilled scientists to Vir with a passion to progress science for patients! We have successfully closed our exclusive worldwide license agreement with Sanofi. Beyond bolstering our clinical pipeline with three T cell engagers in #oncology, we are also complementing our world-class #antibody platform with the highly synergistic and pre-clinically validated PRO-XTEN #masking platform. The potential of these combined platforms in #cancer and #infectiousdisease is immense. I am already looking forward to the impact we will have as we work together to transform the lives of #patients. #PatientsAreWaiting #Tcellengagers #PoweringTheImmuneSystemToTransformLives #TeamVir

📣 NEWS 📣 Today we execute on our expanded strategy to consolidate our growth beyond #InfectiousDiseases. We are proud to bring on board three clinical-stage masked T-cell engagers with potential applications in #oncology and exclusive use of the proprietary PRO-XTEN platform in oncology and infectious disease.   ➡️ Read about it here: https://lnkd.in/gnBcDN2h

We are thrilled to announce that the U.S. FDA has cleared our IND application and granted Fast Track designation for our investigational combination therapy, tobevibart and elebsiran, for the treatment of chronic #hepatitis delta infection. Learn more here: https://bit.ly/4eFyNx5 #hepatitisdelta #hepatitisD #hepD

We’re excited to welcome Ramy Farid, Ph.D., and Norbert Bischofberger, Ph.D. to our board of directors. Their tremendous expertise and strategic insights will be invaluable as we work towards our mission of powering the immune system to transform lives. Learn more about them at these links: https://lnkd.in/gYVgPkP7 (Ramy) https://lnkd.in/gyT62qhj (Norbert)

Our Executive Management Team spent a few days immersed in science with our colleagues at our research site in Bellinzona, Switzerland before heading to Milan for the #EASL Congress 2024. Our exceptional scientists in Bellinzona discovered and developed antibodies that have helped us transform the infectious disease landscape – from Ebola to COVID-19, with much more to come! Angie K. Aine Hanly Jason Franklyn Vanina de Verneuil Marianne D. De Backer, MSc, PhD, MBA Jennifer Towne Mark Eisner Jenny Gumm Ed.D. Brent Sabatini, CPA Corti Davide Carey Hwang, MD, PhD

We’re unveiling new safety and efficacy data from our #hepatitisdelta program in an investor call and oral presentation at #EASLCongress 2024. Check out the preliminary data and learn more about the potential of our investigational regimens to be a meaningful treatment for the most severe form of viral hepatitis: https://bit.ly/4aR3rk7

#VirBiotechnology is at #EASLCongress 2024. So proud of the progress we are making towards our goal of developing a treatment for the millions of people living with #heaptitisdelta worldwide. #HepCantWait